Institution Directory

Clinical trials at Cleveland Clinic

Sites in Cleveland, OH

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1317

Shown on this page

Current sort

Live official records

Conditions: Solid Tumors, Adult
Interventions: HMPL-A251; Drug
Lead sponsor: Hutchmed; Industry
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Denver, Colorado • Plantation, Florida • Tamarac, Florida + 4 more

Conditions: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
Interventions: Tulisokibart, Companion diagnostic ( CDx), Placebo; Drug · Diagnostic Test
Lead sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 14 more

Conditions: Asthma
Interventions: Lunsekimig, Short-Acting Beta Agonists (SABA), Placebo, Fluticasone/Salmeterol, Budesonide/Formoterol, Budesonide/Albuterol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 53
States / cities: Saraland, Alabama • Chandler, Arizona • Sun City, Arizona + 47 more

Conditions: Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Unresectable Fallopian Tube Endometrioid Adenocarcinoma, Unresectable Fallopian Tube High Grade Serous Adenocarcinoma, Unresectable Ovarian Endometrioid Adenocarcinoma, Unresectable Ovarian High Grade Serous Adenocarcinoma, Unresectable Primary Peritoneal Endometrioid Adenocarcinoma, Unresectable Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions: Biopsy Procedure, Carboplatin, Ipatasertib, Paclitaxel; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: San Francisco, California • Augusta, Georgia • Cleveland, Ohio + 5 more

Conditions: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Interventions: Aficamten, Placebo; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 60
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 46 more

Conditions: Acromegaly
Interventions: Debio 4126, Placebo; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 7 more

Conditions: Human Papilloma Virus Related Carcinoma, Tonsillar Squamous Cell Carcinoma
Interventions: Transoral robotic surgery+MRI; Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Chemotherapy-induced Peripheral Neuropathy, CIPN - Chemotherapy-Induced Peripheral Neuropathy
Interventions: High Concentration Capsaicin Patch (HCCP), Placebo patch; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: VX-407; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 26
States / cities: Alabaster, Alabama • Birmingham, Alabama • Los Angeles, California + 21 more

Conditions: Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Interventions: Inobrodib, Pomalidomide, Dexamethasone; Drug
Lead sponsor: CellCentric Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 21
States / cities: Phoenix, Arizona • San Francisco, California • Jacksonville, Florida + 18 more

Conditions: Mitral Valve Regurgitation (Degenerative or Functional)
Interventions: INNOVALVE system; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2034
U.S. locations: 21
States / cities: Los Angeles, California • Palo Alto, California • Naples, Florida + 15 more

Conditions: Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Leucovorin Calcium, Lumbar Puncture, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate, X-Ray Imaging; Procedure · Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 30 Years to 70 Years
Enrollment: 488 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2027
U.S. locations: 531
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 328 more

About this Cleveland Clinic institution page

What this page lists: ClinicalTrials.gov records that list Cleveland Clinic in Cleveland, OH as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Cleveland Clinic

Filter and sort this campus

Live official records

A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

Pre-Op MRI on Margin Status for Transoral Robotic Surgery for HPV+ Tonsillar Squamous Cell Carcinoma

High-concentration Capsaicin Patch for the Prevention of Paclitaxel-induced Peripheral Neuropathy

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

TVMR With the INNOVALVE System Trial - Early Feasibility Study

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

About this Cleveland Clinic institution page